185 related articles for article (PubMed ID: 20834101)
1. Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection.
Akbar SM; Yoshida O; Chen S; Cesar AJ; Abe M; Matsuura B; Hiasa Y; Onji M
Antivir Ther; 2010; 15(6):887-95. PubMed ID: 20834101
[TBL] [Abstract][Full Text] [Related]
2. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B.
Akbar SM; Furukawa S; Horiike N; Abe M; Hiasa Y; Onji M
J Viral Hepat; 2011 Jun; 18(6):408-14. PubMed ID: 20487261
[TBL] [Abstract][Full Text] [Related]
4. Restoration in vitro of impaired T-cell responses in patients with chronic hepatitis B by autologous dendritic cells loaded with hepatitis B virus proteins (R2).
Duan XZ; He HX; Zhuang H
J Gastroenterol Hepatol; 2006 Jun; 21(6):970-6. PubMed ID: 16724980
[TBL] [Abstract][Full Text] [Related]
5. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer.
Akbar SM; Furukawa S; Hasebe A; Horiike N; Michitaka K; Onji M
Int J Mol Med; 2004 Aug; 14(2):295-9. PubMed ID: 15254781
[TBL] [Abstract][Full Text] [Related]
6. Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp.
Farag MM; Tedjokusumo R; Flechtenmacher C; Asen T; Stremmel W; Müller M; Protzer U; Weigand K
Vaccine; 2012 Sep; 30(42):6034-9. PubMed ID: 22867720
[TBL] [Abstract][Full Text] [Related]
7. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection.
Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C
Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082
[TBL] [Abstract][Full Text] [Related]
8. In vitro use of autologous dendritic cells improves detection of T cell responses to hepatitis B virus (HBV) antigens.
Carotenuto P; Artsen A; Niesters HG; Osterhaus AD; Pontesilli O
J Med Virol; 2009 Feb; 81(2):332-9. PubMed ID: 19107973
[TBL] [Abstract][Full Text] [Related]
9. Selective functional deficit in dendritic cell--T cell interaction is a crucial mechanism in chronic hepatitis B virus infection.
Zheng BJ; Zhou J; Qu D; Siu KL; Lam TW; Lo HY; Lee SS; Wen YM
J Viral Hepat; 2004 May; 11(3):217-24. PubMed ID: 15117323
[TBL] [Abstract][Full Text] [Related]
10. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
[TBL] [Abstract][Full Text] [Related]
11. [Rescue of dendritic cells malfunction and loading with HBV proteins in patients with chronic hepatitis B in vitro].
Duan XZ; Su HB; Chen J; Zhang AM; Hu JH; Wang HF
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):328-30. PubMed ID: 20387476
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice.
Shimizu Y; Guidotti LG; Fowler P; Chisari FV
J Immunol; 1998 Nov; 161(9):4520-9. PubMed ID: 9794377
[TBL] [Abstract][Full Text] [Related]
13. Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model.
Bourgine M; Dion S; Godon O; Guillen G; Michel ML; Aguilar JC
Virology; 2012 Aug; 430(1):10-9. PubMed ID: 22591777
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study on dendritic cells stimulated with HBsAg or HBcAg in patients with chronic hepatitis B].
Kang P; Luo SL; Li SC
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):250-2. PubMed ID: 17971936
[TBL] [Abstract][Full Text] [Related]
16. Characterization of T-cell tolerance to hepatitis B virus (HBV) antigen in transgenic mice.
Takashima H; Araki K; Miyazaki J; Yamamura K; Kimoto M
Immunology; 1992 Mar; 75(3):398-405. PubMed ID: 1533387
[TBL] [Abstract][Full Text] [Related]
17. [Immunological and virological efficacy against HBV chronic infection of the therapeutic vaccine composed of HBV core plus PreS1 in HBV transgenic mice].
Li MZ; Chen XC; Zhou BP; Le XH; Xu LM; Wang HS
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Sep; 17(3):277-9. PubMed ID: 15340577
[TBL] [Abstract][Full Text] [Related]
18. Recombinant heat shock protein 65 carrying hepatitis B core antigen induces HBcAg-specific CTL response.
Yang BF; Zhao HL; Xue C; Xiong XH; Zhang W; Yao XQ; Liu ZM
Vaccine; 2007 May; 25(22):4478-86. PubMed ID: 17467856
[TBL] [Abstract][Full Text] [Related]
19. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
[TBL] [Abstract][Full Text] [Related]
20. [The immunization effects of HBV core antigen and surface antigen fusion protein in mice].
Li L; Tian YJ; Shen H; Zhao XP; Yang DL
Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):275-9. PubMed ID: 19403026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
